Hypogonadism

Intramuscular Testosterone Therapy Tied With Rise in Hematocrit

Publish Date May 1, 2023

The risk of hematocrit elevation may depend on testosterone therapy’s route of administration, according to investigators.

Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines

Publish Date January 18, 2023

Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone

Standard Testosterone Threshold Not Accurate for Younger Men

Publish Date November 28, 2022

Age-specific testosterone cutoffs show each 1-year increase in age tied to a 4.3-ng/dL decrease in testosterone level

Testosterone for Hypogonadism Not Associated With Short- to Medium-Term CV Risk

Publish Date September 28, 2022

A study was conducted to determine the cardiovascular safety of testosterone therapy for treatment of hypogonadism.

COVID-19 Hospitalization Risk Higher for Men With Hypogonadism

Publish Date September 15, 2022

Odds of hospitalization higher for men receiving inadequate TTh versus those with normal testosterone concentration while receiving TTh

FDA Approves Oral Testosterone Replacement Therapy Kyzatrex

Publish Date August 4, 2022

The FDA has approved Kyzatrex (testosterone undecanoate) for the treatment of primary and secondary hypogonadism in adult males.

Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk

Publish Date June 17, 2022

No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety

Morbid Obesity Ups Odds of Multiple Urologic Conditions

Publish Date May 14, 2022

Efforts to reduce obesity may cut the prevalence of these urological conditions.

FDA Approves Oral Testosterone Replacement Therapy Tlando

Publish Date April 6, 2022

The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.

Cardiovascular Events, VTE Tied to Polycythemia During Testosterone Therapy

Publish Date January 31, 2022

Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.